Expiration Date: 08/20/2025
Learner Notification
*Please note that you must complete the Post Webinar Evaluation (link below) to receive CE credit.
Speakers
Arianna Campbell, MPH, PA-C
PA, Principal Investigator, Senior Director
VA NCHCS, Marshall Medical Center, The Bridge Center at PHI
Has disclosed no relevant financial relationships
Moderator
Stephanie Weiss, MD, PhD, MS
Staff Research Physician
Translational Addiction Medicine Branch Intramural Research Program National Institute on Drug Abuse National Institutes of Health
Organizer
David Vearrier, MD, MPH
Professor of Emergency Medicine
University of Mississippi Medical Center
Has disclosed no relevant financial relationships
Description
With overdoses deaths exceeding 100,000 yearly, and with an estimated 94% of Americans not receiving SUD treatment, there is an urgent need to scale treatment for opioid use disorder (OUD) across the US. CA Bridge developed an innovative program to initiate medications for opioid use disorder (MOUD) and provide navigation to ongoing treatment within emergency departments over the past 5 years. Utilizing a rapid start, high dose algorithm and developing an ED navigator workforce, CA Bridge has facilitated this implementation in 276 hospitals in California. Learn about this program, the algorithms, and how this is being spread across the country.
Activity Type: Knowledge Based
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives – After attending this program you should be able to:
- Identify opioid use disorder as a chronic disease with a biologic mechanism.
- Implement pathways to treat withdrawal, overdose and OUD with buprenorphine.
- Outline barriers and facilitators to treatment for people who use drugs.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.
Click here to complete the Post Webinar CE Evaluation